综合计算-实验发现α-heterin作为一种多机制,低毒性的抗真菌剂,向Candida albicans CYP51
Xuan Wang1, Yuchun Zhang1, Gansukh Sunderiya1
1Key Laboratory for Space Bioscience and Space Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an, Shaanxi Province 710072, China.
Journal of advanced research
|December 1, 2025
概括
这项研究确定了α-hederin作为一种新型,低毒性的抗真菌剂,向Candida albicans CYP51. 它为开发有效的抗真菌疗法来对抗耐药性真菌感染提供了一个有希望的新策略.
科学领域:
- 菌类学和制药科学 菌类学和制药科学
- 计算化学和药物发现
背景情况:
- 由于Candida albicans感染的发病率和死亡率不断上升,需要新的抗真菌疗法.
- 现有的抗真菌药因毒性和新兴药物耐药性而面临限制.
- 创新的药物发现策略对于开发更安全,更有效的治疗方法至关重要.
研究的目的:
- 通过综合计算方法识别针对Candida albicans CYP51 (14-α-胆固醇脱甲基酶) 的新型抗真菌化合物.
- 选传统中医药系统药理学 (TCMSP) 数据库的潜在的抗真菌候选人.
- 为加速抗真菌药物开发建立一个计算-实验框架.
主要方法:
- 结合分子对接和药模拟的综合计算方法被用于选TCMSP数据库对C. albicans CYP51.1.进行选.
- 确定了两个天然的小分子α-hederin和elemenin,并进行了体外和体内真菌试验.
- 通过分子对接和分子动力学模拟,阐明了抗真菌机制.
主要成果:
- α-Hederin和elemenin被确定为针对C. albicans的新型抗真菌候选物,其最小抑制度 (MIC) 分别为32μg/mL和16μL/mL.
- α-Hederin在体外表现出较低的细胞毒性,并有效抑制了hyphal和生物膜的形成.
- 在体内研究表明,α-hederin在小鼠口腔候群病模型中表现优于可纳,减少了真菌负担和粘附.
结论:
- CYP51已被验证为结构导向抗真菌药物查的高价值标.
- α-Hederin被确定为一个有前途的低毒性,多机制的抗真菌剂.
- 为快速开发抗真菌药物建立了一个计算-实验框架.
相关概念视频
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...